Sciona, Inc. Closes Third Round of Financing for $8.2 Million
Sciona, Inc. has successfully completed its second closing of the company's third round of financing at $8.2 million. Burrill and Company led the round, which also included investors Prelude Trust, BASF Venture Capital Gmbh and Bioventures, Inc.
Sciona develops DNA screens for common gene variants that affect an individual's response to food, medications and the environment. These genetic screens serve as the basis for providing personalized, science-based health and lifestyle advice to consumers and can help companies customize personal care and nutrition products. Sciona's field of genetic personalization is a rapidly growing discipline aimed at optimal health by creating products and services tailored to an individual's genetic makeup.
Sciona has developed an understanding of the relationship between an individual's genetic variation to lifestyle factors and how an individual's lifestyle can be altered by appropriate intervention strategies (i.e. response to diet, exercise, and other environmental factors). Sciona also developed a unique and critically important "consumer friendly" vehicle to deliver the information. The Cellf(TM) genetic screen gives consumers nutritional guidelines -- based on individual genetic profiles -- to empower individuals to make better health decisions specific to their individual genetic makeup. The Cellf kit includes genetic information on the following health conditions: insulin sensitivity, B-vitamin metabolism, detoxification, heart and bone health, antioxidant metabolism and inflammation.
In addition to its genetic personalization work, Sciona provides research capabilities for large food, nutritional supplement and functional food companies interested in analyzing particular product ingredients as they relate to the normal genetic variations found in healthy individuals. This type of research makes it possible to greatly increase product effectiveness by introducing unparalleled product personalization.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Comprehensive genetic characterization of primary immunodeficiency - Genetics of primary immunodeficiencies on an unprecedented scale explored
Microdosing and human drug absorption studies under the spotlight in live web cast
Epizootic_lymphangitis
Ataxia_telangiectasia
MerLion Pharmaceuticals announces the completion of a merger with Combinature Biopharm AG and Athelas SA
Gen-Probe Licenses Technology from AdnaGen That May Increase Accuracy of Molecular Diagnostic Tests for Cancer - Innovative 'Immunocapture' Technology Combined with NAT Also May Help Determine Aggressiveness of Malignancies and Aid in Patient Monitoring

Zipper Triggers Bacterial Invasion - Researchers discover new strategy germs use to invade cells
Galapagos and ProStrakan receive additional milestone payment in antibody collaboration
